All News

QOL data from DESTINY-Breast06 support T-DXd as a new therapeutic option in previously treated HER2-low and HER2-ultralow metastatic breast cancer.

A median EFS of 40.1 months was noted in patients resectable NSCLC given perioperative nivolumab vs placebo.

In patients with early breast cancer, hypofractionated radiation was noninferior to normofractionated radiation regarding lymphedema risk.

Subgroup analysis in a phase 3 trial show OS benefits with the ramucirumab-based regimen in female patients and those with left-sided tumors.

A pembrolizumab regimen for patients with early-stage triple-negative breast cancer yielded improved overall survival.

The addition of pembrolizumab to chemotherapy with or without radiation did not improve DFS across the intent-to-treat population of KEYNOTE-B21.

Superior efficacy outcomes were noted when adagrasib was used to treat patients with KRAS G12C NSCLC and among those with brain metastases.

Significant survival benefits were observed with Radium-223 plus enzalutamide in patients with metastatic castration-resistant prostate cancer.

The primary end point of progression-free survival was met with retifanlimab to carboplatin and paclitaxel in patients with metastatic SCAC.

The safety profile of nivolumab/relatlimab/chemotherapy in RELATIVITY-104 was comparable with prior reports of each individual agent.

Pembrolizumab combination improved efficacy outcomes vs chemoradiotherapy alone in patients with advanced cervical cancer.

Neoadjuvant endocrine therapy or paclitaxel with trastuzumab/pertuzumab elicited significant survival in HR-positive, HER2-positive early breast cancer.

High TILs may predict who may have a reduced risk for disease relapse or death in patients with early HER2-positive breast cancer treated with trastuzumab.

Amivantamab plus chemotherapy also improved time to symptomatic progression among patients enrolled on the MARIPOSA-2 trial.

Data from the GALAXIES-Lung 201 trial found efficacy improvement in patients with advanced NSCLC.

Patients with radioiodine-refractory differentiated thyroid cancer appear to derive benefit from lenvatinib in community and academic settings.

Findings from DESTINY-Breast12 support the use of T-DXd for patients with HER2-positive metastatic breast cancer.

BMS-986012 in combination with nivolumab/chemotherapy showed numerical PFS improvements in those with and without brain metastases at baseline.

The phase 3 CAPItello-290 trial of capivasertib plus paclitaxel did not meet its primary end point of improved overall survival in the frontline setting of metastatic triple-negative breast cancer.

Final analysis data from LITESPARK-005 support belzutifan as a treatment for patients with previously treated advanced clear cell RCC.

The magnitude of benefit with durvalumab was particularly consistent within prophylactic cranial irradiation and radiation subgroups in the ADRIATIC trial.

Patients with NSCLC across various subgroups did not see a disease-free survival benefit with adjuvant durvalumab compared with placebo.

Genomic subtype was associated with relapse, occurring in nearly 50% of PAX5-altered pediatric acute lymphoblastic leukemia cases.

Patients with certain solid tumors may be eligible for subcutaneous atezolizumab and hyaluronidase-tqjs, which is now approved by the FDA.

Updated findings from the AEGEAN trial support perioperative durvalumab as a new therapy option for those with resectable non–small cell lung cancer.

Phase 2 data show meaningful efficacy with taletrectinib regardless of whether patients with ROS1-positive NSCLC previously received tyrosine kinase inhibitors.

Early data appear to highlight encouraging efficacy and tolerability outcomes with Bria-IMT in patients with metastatic breast cancer.

Developers anticipate releasing full efficacy results from the phase 2 THIO-101 trial in late 2024.

Confirmed partial responses with firmonertinib occurred across a range of EGFR PACC mutations among patients with NSCLC in the phase 1b FURTHER trial.

Patients with EGFR-mutated NSCLC had sustained HRQOL when treated with amivantamab plus lazertinib vs osimertinib.